Immunomedics, Inc. (IMMU) Receives 4 New Patents for Expanded Antibody-Drug Conjugate Program
Immunomedics (NASDAQ: IMMU) this morning announced it has received patent protection for the use of IMMU-132, the company’s lead antibody-drug conjugate (ADC) for the treatment of patients with Trop-2-positive cancers. Based on “encouraging objective response rates and durable responses” from an ongoing phase 2 clinical study, Immunomedics said it plans to expand its ADC program to include liquid tumors. As a result, the company created and received a patent for IMMU-140, as well as another ADC targeting B-cell hematologic malignancies. All three new ADC patents will expire in July 2033. Additionally, Immunomedics’ IBC Pharmaceuticals, Inc. subsidiary has received a patent…